Posts

Latest DeiCell Dispatch

BIOSECURE Turns Supplier Dependence Into an Evidence Question

-
Image
DEICELL SYSTEMS | REGULATORY EXPLAINER July 7, 2026 BIOSECURE Makes Supplier Dependence a Readiness Test BIOSECURE pressure reaches beyond procurement teams by forcing biotech, medtech, CDMO, CRO, supplier, quality, regulatory, and diligence teams to prove how supplier choices, outsourced work, contract chains, and change-control paths are understood. A supplier decision that once looked like a technical fit or capacity decision can become a reviewable operating record. Under the introduced H.R. 7085 BIOSECURE Act text, federal agencies would be restricted from procuring covered biotechnology equipment or services from a biotechnology company of concern and from contracting with entities that use those covered services or equipment in performance of a federal contract. The bill also addresses loan and grant funds. For operating teams, the pressure sits in the supplier file, the quality agreement, the subcontractor record, the data pathway, and the change-control rationale....
Read more

GLP-1 Growth Is Pushing Manufacturing Evidence Earlier

-
Image
DEICELL SYSTEMS | MARKET PRESSURE BRIEF July 9, 2026 GLP-1 Growth Is Pushing Manufacturing Evidence Earlier GLP-1 demand is moving supplier qualification, process-transfer rationale, batch documentation, deviation control, and QMS scope decisions into the foreground earlier for biotech and medtech teams tied to obesity, diabetes, delivery systems, CDMO capacity, and adjacent manufacturing models. GLP-1 growth is forcing manufacturing evidence into the foreground before many emerging teams are staffed to manage it. The signal is visible in the data. Deloitte’s 2026 pharmaceutical innovation analysis shows headline late-stage R&D returns improving to 7.0 percent in 2025, but the same analysis shows a much weaker 2.9 percent return when GLP-1/GIP mechanisms are excluded. Average forecast peak sales per asset rose to $598 million in 2025, but the report ties that increase heavily to a small number of high-forecast GLP-1/GIP assets. That concentration changes the operating...
Read more

Why Biotech M&A Is Rising Again, and What Buyers Are Screening For

-
Image
DEICELL SYSTEMS | MARKET ANALYSIS Patent Cliffs Are Driving Biotech M&A, but Readiness Still Decides the Deal This article explains why biotech deal activity is accelerating and why it matters for teams whose assets may attract buyer interest before their operating infrastructure is ready to support diligence. Biotech deal activity is rising again, yet the important point is not that the market feels more optimistic. Large pharmaceutical companies are moving under revenue pressure as major products approach loss of exclusivity, so acquisitions have become a faster way to close future pipeline gaps than relying on internal development alone. That surface signal matters, but it is not the whole issue. A more active M&A market does not lower the standard for emerging biotech teams. It changes the operating burden around the asset, because interest from buyers quickly turns into questions about documentation, ownership, man...
Read more